ROSETTA SIGNED
Deciphering the Role of aberrant glycOSylation in the rEsponse to Targeted TherApies for breast cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ROSETTA project word cloud
Explore the words cloud of the ROSETTA project. It provides you a very rough idea of what is the project "ROSETTA" about.
Project "ROSETTA" data sheet
The following table provides information about the project.
| Coordinator |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 175˙572 € |
| EC max contribution | 175˙572 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2019 |
| Funding Scheme | MSCA-IF-EF-RI |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-04-01 to 2022-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | NL (ROTTERDAM) | coordinator | 175˙572.00 |
Map
Project objective
Resistance and cancer progression remain a major obstacle to the successful treatment of cancer. In HER2 breast cancer, the development of targeted therapies such as trastuzumab, has revolutionized the treatment for these cancer patients. However, a significant number of patients develop resistance. In this realm, my previous work focused on understanding the crosstalk of interconnected signaling pathways in HER2 cancer cells that drive tumorigenesis and undermine the efficacy of current treatments. The research goal of this proposal is to provide a new focus to the challenge of resistance by deciphering the role of glycosylation in driving resistance to HER2-targeted therapies. Aberrant glycosylation of proteins is a hallmark in cancer and has been linked to multiple processes such as invasion, angiogenesis and modulation of the immune response. The receptor HER2, the main driver of HER2 cancers, is heavily glycosylated and is the target of current antibody-based treatments, including trastuzumab. In this scenario, this proposal aims to (1) identify glycosylation-related genes associated with incomplete pathological response to trastuzumab to (2) dissect their role on trastuzumab binding and (3) assess their impact in the response to trastuzumab mediated by immune cells. This research plan will be accomplished combining the analysis of clinical data from tumor biopsies, the use of trastuzumab-resistant tumor-derived breast cancer cell lines and, the implementation and imaging of 3D heterotypic cultures of cancer cell line-derived spheroids and immune cells. Thus, this proposal addresses a largely unexplored layer of complexity in cancer biology – the role of glycosylation in resistance to targeted therapies – and holds the potential to identify new markers of response to therapies and open the path to new therapeutic options for the improvement of current treatments.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ROSETTA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ROSETTA" are provided by the European Opendata Portal: CORDIS opendata.